Chinese firm Sinovac to boost production capacity to 600 mn doses for Covid-19 efforts

Indonesia has received 1.2 million doses of its experimental vaccine and is expected to approve it for use soon.

The Associated Press December 08, 2020 14:07:32 IST
Chinese firm Sinovac to boost production capacity to 600 mn doses for Covid-19 efforts

This October 2020 photo provided by Pfizer shows part of a "freezer farm," a football field-sized facility for storing finished COVID-19 vaccines, under construction in Kalamazoo, Michigan. AP

Chinese vaccine company Sinovac announced Monday that it is planning to complete a new facility to double its annual vaccine production capacity to 600 million doses by the end of the year, while also securing a $500 million investment in a boost to its COVID-19 vaccine development efforts. The company is currently conducting the last stage of clinical trials for its vaccine candidate in Brazil, Turkey and Indonesia and is among the frontrunners of China's vaccine efforts.

China has at least five COVID-19 vaccine candidates running late stage clinical trials across more than a dozen countries.

Sino Biopharmaceutical Ltd., a pharmaceutical conglomerate, bought a 15 percent stake in Sinovac for an investment of $500 million. The funds will allow the company to “improve our vaccine sales capabilities, expand in Asia markets, develop and access new technologies, and most importantly, accelerate our efforts to help combat the global pandemic," Sinovac CEO Yin Weidong said in a statement.

On Sunday, 1.2 million doses of its experimental vaccine arrived in Indonesia and are expected to be approved for use soon.

Sinovac's candidate is a two-dose inactivated vaccine, an old-school technology in which a live virus is killed and then purified. It can be stored at 2 to 8 C (36 to 46 F), within the range of a normal refrigerator, unlike some other vaccines candidates that require far lower temperatures.

Sinovac's experimental vaccine is currently approved for emergency use in China, although it has not yet obtained final market approval. Under emergency use, it has been distributed to groups the Chinese government deemed suitable, including front-line medical workers and border personnel.

The latest public data from the company, published in the science journal Lancet, showed its candidate produced lower levels of antibodies in people than those who have recovered from COVID-19 .

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

CIA declassifies hundreds of official docs on UFO sightings, research from 1970s onwards
World

CIA declassifies hundreds of official docs on UFO sightings, research from 1970s onwards

A dossier filled with files on Unidentified Aerial Phenomena (UAPs) was published on The Black Vault website on Thursday.

Megalodon shark fossils suggest that newborns were larger than adult humans: Study
science

Megalodon shark fossils suggest that newborns were larger than adult humans: Study

The newborn would have been large enough to be a fierce predator of the seas, and not need to compete for food.

'Recoiling' black hole in a nearby star cluster keeps slipping detection, baffling scientists
science

'Recoiling' black hole in a nearby star cluster keeps slipping detection, baffling scientists

Recoiling black holes, like the one in question, are hypothetical objects that are yet to be definitively spotted.